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Editorial on the Research Topic
Advances in Biological Approaches to Treating Resistant/Refractory Obsessive-Compulsive and
Related Disorders
Obsessive-compulsive disorder (OCD) is a severe and debilitating neuropsychiatric condition that
has an estimated lifetime prevalence of 2.5–3.0% of the general population (1). Approximately 40%
of patients treated for OCD do not respond to standard and second-line augmentation treatments
(2). Treatment-refractory OCD tends to have a chronic and disabling course. Although
psychological interventions, namely exposure and response prevention (ERP), have been shown
to be effective in treating OCD and as an augmentation strategy for poor response to selective
serotonin reuptake inhibitors (SSRIs) (3), many patients cannot engage in exposure therapy or do
not respond to such treatments. Some patients with OCD also have adverse reactions to SSRIs and
this makes alternative biological options for treating OCD more attractive. With increasing interest
in biological therapies for OCD such as deep brain stimulation (DBS), it is important that advances
in biological approaches to treating treatment resistant OCD are evaluated.
While examining the issue of treatment resistance in OCD, one must evaluate not only novel
biological treatments, but also novel theories regarding the etiology of OCD. Recent studies suggest
that OCD results from a dysfunction in the cortico-striatal-thalamo-cortical circuit (CSCT). These
circuits become hyperactive or hyperconnected, and they self-excite a runaway positive feedback
loop (4). This self-excitatory positive feedback loop is thought to lead to an urge to perform
compulsions, which in turn consolidates and strengthens the repetitive and strong urge to perform
compulsions (5). This neuroanatomical model of OCD has formed the basis for neuroanatomically
based treatments for OCD, such as deep brain stimulation (DBS). Specific targets in the application
of deep brain stimulation (DBS) are striatal areas, including the ventral internal capsule/ventral
striatum, the nucleus accumbens, the subthalamic nucleus, the anterior limb of the internal capsule,
and the inferior thalamic peduncle (6). DBS has been associated with response rates of up to 60%
(7). However, Senova et al. propose that DBS may need an individualized approach as different
OCD symptoms may need to be treated by targeting different neuroanatomical sites.g February 2020 | Volume 11 | Article 931
Pasquini et al. Editorial: Treating Resistant/Refractory OCDFurthermore Copetti et al. suggest that patients who had been
suffering fromOCDfor longer periods of timeweremore treatment
resistant and that the impact of DBS on personality may not be a
significant issue. In addition to advances in the understanding of
the neuroanatomical targets that might be useful for treating
treatment resistant OCD, there have also been advances in our
understanding of the neurochemistry of OCD.
Glutamate for example, is the primary neurotransmitter
within the implicated CSCT model for dysfunction in OCD.
Glutamate can act as a neuronal excitotoxin, leading to rapid or
delayed neurotoxicity (8). Carbarkapa et al. remind us of the
comorbidity between OCD and attention deficit hyperactivity
disorder and some of the treatment implications for OCD while
de Avila et al. and Perris et al. remind us of the potential role ofFrontiers in Psychiatry | www.frontiersin.org 2dopamine in the pathophysiology of OCD as they explore the
relationships between OCD and varying levels of insight and
OCD and schizotypal personality disorder.
This short series of articles highlights more recent attempts to
understand treatment resistance in OCD and provides hope to
clinicians and patients suffering from OCD. The articles also
encourage further research that attempts to understand the
heterogeneity of OCD and to tailor treatments for patients
with treatment resistant OCD.AUTHOR CONTRIBUTIONS
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